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Abstract. Background: Positron emission tomography-
computed tomography (PET-CT) is currently not established
in the management of recurrent ovarian cancer. Here, its
value in diagnosis and therapy planning was evaluated.
Patients and Methods: Seventy patients received PET-CT for
suspicion of recurrent ovarian cancer. PET-CT and surgery
were reviewed to analyze the accuracy in the diagnosis of
recurrence and prediction of full resectability. Results: PET-
CT showed disease relapse in 63 of 70 patients, with full
sensitivity and specificity. Thirty cases were operated on.
PET-CT indicated full resectability in 24, but in fact only
incomplete resection was possible in three cases. Thus
sensitivity and specificity for the identification of full
resectability were 100% and 66% , respectively. Seven
negative results in PET-CT were confirmed by a relapse-free
follow-up of 1 year. Conclusion: PET-CT offers reliable
detection of recurrent ovarian cancer. Although diagnostic
accuracy in the prediction of full resectability is limited,
surgical planning is improved by identifying sites of
intraperitoneal involvement.
Being the third most common cancer of the female genital
tract, ovarian cancer is the leading cause of death related to
gynecological malignancies (1). Due to a lack of early
clinical symptoms, ovarian cancer is often diagnosed at an
advanced stage (1). Primary treatment includes operative
cytoreduction and a subsequent platinum-based combined
chemotherapy. Response rates to this standard primary
treatment range at around 80% , but even with this high
sensitivity, survival rates are low and 60-70% of patients
with ovarian cancer relapse or die within 5 years of diagnosis
(2). The importance of debulking in recurrent ovarian cancer
was demonstrated in a retrospective data analysis (3-5). In a
retrospective study, Harter and colleagues found that only
those patients in whom a macroscopic tumor-free resection
could be achieved benefited from surgery in terms of overall
survival (6). Regarding these aspects of patient management,
it is necessary to find a diagnostic tool to select patients who
benefit from surgery and to identify those who are better off
with primary systemic therapy, preferentially as an
interdisciplinary approach involving radiologists, nuclear
medicine physicians and gynecological or oncological
surgeons.
A continuous rise of the CA-125 level is frequently a first
sign of recurrence in ovarian cancer that precedes clinical
symptoms or evidence in imaging by about 6 months (7). As
a differentiation between localized and diffuse tumor spread
is not possible based on tumor markers, sufficient diagnostic
imaging is necessary in suspicion of relapse. The purpose of
diagnostic imaging is to assist treatment planning, e.g. in the
indication of operative and or systemic therapy. Computed
tomography (CT) offers the possibility to cover the whole
abdomen and to detect lymph node abnormalities, but the
assessment is generally based on morphological criteria and
the size of lesions rather than the actual detection of
malignant tissue (8). Therefore, it has limited value in
detecting microscopic and small macroscopic disease,
especially small peritoneal lesions. Moreover, it is difficult
to distinguish benign postoperative changes from tumor
relapse in CT (9).
Therefore, whole-body positron emission tomography
computed tomography (PET-CT) using 18F-fluoro-
deoxyglucose (18F-FDG) may be a useful diagnostic tool in
recurrent ovarian cancer. It was described to be effective in
distinguishing between benign and malignant disease in lung,
colorectal and head and neck cancer (10), and its applicability
has also been shown for ovarian cancer (11). A prospective
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study by Sironi et al. based on the use of 18F-FDG with a
combined PET-CT system has demonstrated good results in
the follow-up of patients with ovarian cancer after first-line
treatment (12).
The aim of this study was to evaluate the use of PET-CT
in recurrent ovarian cancer focusing on sensitivity, specificity
and accuracy of 18F-FDG PET-CT for detecting ovarian
cancer relapse in patients with clinical signs of recurrent
disease or elevated CA-125 levels in the clinical follow-up.
A further aim of this study is to assess whether PET-CT can
assist treatment planning by predicting resectability and by
localizing tumor tissue for surgical planning.
Patients and Methods
Patients. All women undergoing PET-CT for investigation of
possible recurrent epithelial ovarian cancer at our institution
between November 2003 and January 2008 were included in a
retrospective analysis. Clinical data of the patients’ disease were
available from patient charts, aftercare files and follow-up surveys.
Serum tumor markers (at primary diagnosis, after chemotherapy and
in follow-up), recent imaging results and indication for PET-CT
were also included in the assessment. The standard follow-up
consists of physical examination and evaluation of serum CA-125
and CA-72-4 levels (automated enzyme immunoassay; Elecsys,
Roche Diagnostics, Penzberg, Germany) at 3-month intervals for
the first 2 years after completion of primary therapy and every 6
months afterwards.
Indication for PET-CT was based on clinical symptoms,
suspicion of relapse at physical examination, or a rise of blood
tumor markers. Suspicion of relapse was defined as an elevation of
serum CA-125 above the normal range (>35 U/ml) after achieving
normal levels, or a doubling of the lowest level after primary
therapy. Contraindications to PET scanning were a blood glucose
level higher than 140 mg/dl, a history of diabetes and intolerance of
PET-CT due to claustrophobia.
Integrated PET-CT. PET-CT was performed using a Philips Gemini
System (Philips, Eindhoven, Netherlands). After a fasting period of
at least 6 hours, 250 MBq 18F FDG were administered at normal
blood glucose levels and the patient was then instructed to rest in the
supine position for 45 minutes to avoid non-specific muscular
uptake. Twenty milligrams of furosemide were additionally injected
intravenously to limit the radiation exposure of the urinary bladder
and to increase the diagnostic accuracy for the urinary tract (13). In
addition, 20 mg of butylscopolamine were administered to reduce
non-specific intestinal uptake due to bowel peristalsis (14). Iso-
osmotic mannitol was applied as negative oral contrast material to
improve bowel assessment without interfering with the attenuation
correction. A low-dose CT scan was acquired for attenuation
correction at 120 kVp tube potential with 30 mAs current at a pitch
of 1.5 and 2×5 mm collimation, covering a range from the skull base
to the thighs. Positron emission scans were acquired with a 144×144
matrix and 10 cm field of view during 3 minutes per table position,
so that 12 table positions were required on average to cover the
range. The subsequent diagnostic CT scan was acquired during a
single breath-hold, 70 seconds after administration of 120 ml of non-
ionic contrast material (Ultravist, 623 mg/ml Iopromide; Bayer
Schering, Berlin/Germany) at a higher tube current of 160 mAs and
otherwise identical parameters as the previous low-dose scan. PET
data were reconstructed with three-dimensional maximum-likelihood
algorithm (Ramla) with attenuation correction. Both CT and PET
data were reconstructed in 5-mm slices. With specific software
(Syntegra, Philips), CT and PET datasets were reviewed on a post-
processing workstation in axial, coronal and sagittal orientation
(Figure 1a) and fused with color-coded superimposition of the PET
(Figure 1b) on the CT image (Figure 1c).
Image analysis. The images were reviewed by a radiologist
experienced with CT and a nuclear medicine physician experienced
with PET. The readers were unaware of the patients’ serum CA-125
levels and of results of other imaging modalities.
For review, attenuation-corrected PET images, CT scans and co-
registered PET-CT images were displayed simultaneously. The
presence of abnormally increased FDG uptake was noted and its
exact anatomical location was indicated on the CT. In the report, the
readers indicated the presence or absence of elevated specific uptake
values which raised suspicion of distant metastases. Moreover, they
differentiated abdominal lesions, classifying them by location in the
lower pelvis, pelvic lymph nodes, para-aortal lymph nodes or in the
peritoneum, the latter including diffuse peritoneal carcinosis. All
examinations were interpreted by both physicians individually and
in consensus.
Surgical procedure. A secondary laparotomy for cytoreductive
surgery was considered for patients if PET-CT raised suspicion of a
relapse and a possibly resectable tumor spread. Surgery was
conducted with palliative indication in two patients to reduce their
clinical symptoms from bowel obstruction. All operative procedures
were performed by an experienced oncological gynecological
surgeon. Intra-abdominal tumor spread was classified by location
according to the sites assessed in the PET-CT evaluation. In
addition, the surgeon reported whether a macroscopically tumor-free
resection was achieved.
Data analysis. Calculations of sensitivity, specificity, accuracy and
positive and negative predictive values for tumor detection with
PET-CT were performed on a per-patient basis, regarding intra-
operative findings and results at histological analysis after surgery as
standards of reference. Additionally, the respective values were
calculated for the prediction of complete resectability in patients
with intra-abdominal findings and without distant metastases. To
account for the limited sample size of negative findings, 95%
confidence intervals were also included. To quantify the agreement
between imaging and operative findings, diagnostic accuracy was
also calculated for the individual sites of intra-abdominal
involvement. All statistical tests were performed with MedCalc
software (MedCalc, Mariakerke, Belgium).
Results
Histological findings and patient characteristics. Altogether,
70 patients who had received a PET-CT for suspicion of
recurrent ovarian cancer were included in the analysis (Table
I). The patients’ age at primary diagnosis ranged from 20 to
83 years (mean age 56) and averaged 59 years at relapse. All
patients underwent primary cytoreductive surgery at initial
diagnosis and subsequently received a platinum-based
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chemotherapy. Suspicion of relapse was based on an increase
of serum tumor markers in 49 cases (CA-125: 158.0±173.9
U/ml and CA 72-4: 3.7±5.0 U/ml). In 28 patients, there were
clinical symptoms such as ascites, intestinal symptoms,
abdominal pain or deteriorated general condition. The median
relapse-free interval was 30.4±22.4 months. Of all patients,
80% had an advanced ovarian cancer at initial diagnosis
(FIGO I (5/70), FIGO II (9/70), FIGO III (49/70), FIGO IV
(7/70)). The most common histological tumor type was a
serous-papillary ovarian cancer with 69% incidence (48/70),
followed by adenocarcinomas at 11% (8/70).
PET-CT imaging findings. In PET-CT, a relapse was found
in 63 of 70 patients. Seven patients were not found to have a
relapse, and a tumor-free follow-up of at least 1 year
confirms these negative results. Of the 63 positive cases,
there was an indication for laparatomy in 30: in 28 patients
the aim was full resection and in two patients there was a
palliative indication to resolve bowel obstruction. Tumor
tissue was removed and confirmed histologically in all
operated patients, confirming the positive result of PET-CT.
In the remaining 33 patients with relapse suspected in PET-
CT, there was no indication for surgery because in 22 there
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Figure 1. Coronal reconstruction of a simultaneously acquired PET-CT
scan of an ovarian cancer patient. (a) Color-coded PET, (b)
corresponding CT reconstruction, (c) fused reconstruction with CT in
grey scale and color-coded PET superimposition. The PET scan reveals
two foci of increased glucose utilization. With the co-registered CT, one
lesion can be identified as a 3 cm × 2 cm soft tissue mass ventral of the
spleen, the other lesion dorsal of the caecum.
Table I. Patient characteristics.
Number of patients 70
Relapse (% ) 90
Age at primary diagnosis (years) 56 (20-83)
Relapse-free interval (months) 30
Clinical symptoms at relapse (% ) 40
Tumor marker increase at relapse (% ) 70
CA-125 at relapse (U/ml) 158.0±173.9
CA 72-4 at relapse (U/ml) 3.7±5.0
was evidence of distant metastases and irresectable diffuse
peritoneal spread was present in 23; in 12 there were both
distant and peritoneal metastases. Thus, a histological
confirmation was not available in these patients, except for
three in whom biopsies were taken from mediastinal lymph
nodes to confirm relapse. However, systemic chemotherapy
was initiated and the positive finding in PET-CT was then
confirmed by response to systemic therapy in all patients,
evident either by a drop of tumor markers or regression of
soft tissue masses in follow-up imaging, except for two
patients in whom there was progressive disease. Thus,
regarding the diagnostic accuracy of PET-CT per patient in
the diagnosis of recurrence, there were no false-positive and
no false-negative results, yielding full sensitivity and
specificity, with 95% confidence intervals of 94-100% and
63-100% , respectively (Table II).
In the 30 patients with an indication for surgery, full
resectability was expected at PET-CT imaging in 24. In 21
patients, the tumor was removed without macroscopic
remnants, while only an incomplete resection was possible in
9 cases, two of those with primary palliative indication. Thus,
sensitivity and specificity of PET-CT in the identification of
fully resectable patients were 100% and 66% , with 95%
confidence intervals of 84-100% and 30-92% , respectively.
Altogether, PET-CT described 113 lesions with suspicion
of recurrence (17 lesions in the lesser pelvis, 9 lesions in the
region of pelvic lymph nodes, 17 lesions in the region of
para-aortic lymph nodes, 38 peritoneal and 32 distant
lesions). Regarding the site of involvement in the abdomen,
there was an excellent correlation between PET-CT and
operative findings, with full sensitivity and specificity for all
sites except for para-aortic lymph nodes, in which
histological analysis revealed one metastasis that had not
been detected in PET-CT, resulting in a sensitivity of 83%
(9/9 lesions in the lesser pelvis, 5/5 lesions in the region of
pelvic lymph nodes, 10/11 lesions in the region of para-
aortic lymph nodes, 11/11 distant intraperitoneal lesions)
(Table III). In contrast, diffuse peritoneal carcinosis was only
detected in 15 out of 19 cases, corresponding to a sensitivity
of only 79% , which was the limiting factor for macroscopic
tumor-free resection in those four patients.
Serum tumor markers. An increase of a tumor marker
according to defined criteria, i.e. elevation of a serum marker
above the normal range after achieving normal levels or a
doubling of the lowest level achieved after primary therapy,
was the most frequent indication for PET-CT imaging in our
patient group. Of the patients with suspected tumor
recurrence, 70% had elevated tumor markers, while clinical
symptoms occurred in only 40% of the patients. Suspicion
of recurrence was based on an increase of serum tumor
markers CA-125 in 49 and CA 72-4 in 7 cases. All patients
with elevated levels of CA 72-4 also had a high CA-125.
Median levels at the time of PET-CT imaging were
158.0±173.9 U/ml for CA-125 and 3.7±5.0 U/ml for CA
72-4. Of seven patients in whom there was no evidence of
recurrence in PET-CT, only two had elevated tumor marker
levels. However, there was no statistically significant
relationship between serum tumor markers and the extent or
site of recurrence as observed in PET-CT imaging or at
surgery, neither for CA-125 nor CA 72-4. Moreover, there
were no differences in tumor marker levels for the
histological tumor types.
Discussion
The oncological follow-up of ovarian cancer patients consists
of physical and gynecological examination, clinical history
and imaging. Even though tumor markers such as CA-125
are not part of routine follow-up according to guidelines,
they are widely used. They have been described to occur as
the first evidence of recurrent ovarian cancer, typically 6
months prior to clinical signs. A rise of tumor markers often
triggers a cascade of further diagnostic procedures,
especially imaging. With the combination of functional and
anatomical information, PET-CT offers a powerful tool in
oncological imaging. According to our results, early
recurrent ovarian cancer can be detected by this imaging
modality independently of the absolute value of CA-125. In
our population, there were ten patients with a serum CA-125
of 35 U/ml or less. All of them showed a positive PET-CT
scan. This is in agreement with data by Simcock et al. which
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Table III. Sensitivity of localization.
Sensitivity (% )
Lesser pelvis 100
Pelvic lymph nodes 100
Para-aortic lymph nodes 91
Distant lesions 100
Peritoneal carcinosis 79




Sensitivity (% ) 100 94-100
Specificity (% ) 100 63-100
Diagnosis of full resectability
Sensitivity (% ) 100 84-100
Specificity (% ) 66 30-92
showed positive PET-CTs for patients with normal CA-125
(15). We found no evidence of a relation between anatomical
site of tumor tissue and serum CA-125 or CA 72-4. Further
analysis did not show any relationship between tumor
markers and histological tumor type as there were no
significant differences between serous-papillary tumors,
adenocarcinomas and others. Thus, serum tumor markers do
not seem to reveal any information on the type of tumor
tissue, the extent or the localization of the recurrence. These
findings are in agreement with other studies which showed
a limited correlation between tumor marker levels and extent
of disease and no association between histological type and
the pattern of recurrence in PET-CT (16, 17).
Apart from the suspicion of recurrent disease mostly
based on the PET information, the CT scan was able to
identify the exact site of recurrence (Figure 1a-c). Surgical
planning can be improved by the exact knowledge of sites
and the extent of the tumor, including the involvement of
intestinal or urinary tract and abdominal wall, with the
possibility of consulting surgical or urological colleagues.
Importantly, PET-CT can also help to identify patients in
whom a complete surgical resection is possible and thus
preoperatively differentiates between a curative and a
palliative approach with respect to radicality. Bristow et al.
have described PET-CT to be a sensitive tool to assist the
early identification of disease suitable for surgical resection
(18). Our data are in agreement with this finding in that 21
of our patients were correctly identified for radical surgery.
In another four, a macroscopically tumor-free resection was
not possible due to diffuse peritoneal spread which had not
been identified in PET-CT. This supports the finding of
other studies which reported diffuse peritoneal carcinosis
to be difficult to detect with PET-CT (19). Although PET-
CT may fail to detect peritoneal carcinosis of recurrent
ovarian cancer (20), positive findings do help to optimize
the therapeutic strategy in these patients. Yet, there are no
better imaging modalities available for the detection of
diffuse peritoneal carcinosis. CT, which is used most
frequently for suspected relapse of ovarian cancer, has a
sensitivity of only 47% and a specificity of 87% with
reference to second-look operation (21). Moreover, CT has
been shown to have quite a low negative predictive value
for this indication as Makhija et al. reported that PET-CT
could identify recurrent disease in 62% of patients with
negative CT scans (22). PET scans alone have been
described to be a reliable tool to detect recurrent or residual
ovarian cancer (17), although its diagnostic value is limited
with respect to the anatomic localization of tumor and
small tumors. Thus, PET-CT can aid surgical planning by
combining metabolic and anatomical information. In the
patients with recurrence in whom there was no indication
for surgery, PET-CT was a useful tool to avoid unnecessary
surgery or laparoscopy.
Conclusion
PET-CT represents a useful diagnostic means in the workup
of clinically or serologically suspected relapse of ovarian
cancer. The modality offers a reliable detection of recurrent
ovarian cancer and can assist surgical planning by identifying
sites of intraperitoneal involvement. Additionally, the
exclusion or detection of distant metastases can support
general therapy planning.
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